Analyst Price Targets — KRRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 11:27 am | Steve Seehouse | Cantor Fitzgerald | $22.00 | $11.50 | StreetInsider | Korro Bio (KRRO) PT Raised to $22 at Cantor Fitzgerald on UCD Potential |
| March 13, 2026 8:26 am | Ryan Deschner | Raymond James | $23.00 | $11.50 | StreetInsider | Raymond James Upgrades Korro Bio Inc. (KRRO) to Outperform |
| February 18, 2026 9:23 pm | — | Raymond James | $18.00 | $11.24 | StreetInsider | Clear Street Upgrades Korro Bio Inc. (KRRO) to Buy |
| January 29, 2026 11:08 am | — | H.C. Wainwright | $20.00 | $11.69 | TheFly | Korro Bio upgraded to Buy from Neutral at H.C. Wainwright |
| January 29, 2026 9:58 am | — | Chardan Capital | $15.00 | $11.69 | TheFly | Korro Bio upgraded to Buy from Neutral at Chardan |
| January 28, 2026 11:12 pm | Yasmeen Rahimi | Piper Sandler | $30.00 | $11.69 | TheFly | Korro Bio upgraded to Overweight from Neutral at Piper Sandler |
| January 28, 2026 12:09 pm | Myles Minter | William Blair | $10.00 | $11.17 | StreetInsider | William Blair Reiterates Market Perform Rating on Korro Bio Inc. (KRRO), 'early stages of its pipeline with clinical data unlikely until 2027' |
| January 28, 2026 11:54 am | — | Oppenheimer | $22.00 | $10.74 | TheFly | Korro Bio upgraded to Outperform from Perform at Oppenheimer |
| January 27, 2026 9:10 pm | Steve Seedhouse | Cantor Fitzgerald | $21.00 | $10.74 | TheFly | Korro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald |
| April 16, 2025 8:24 am | Keay Nakae | Chardan Capital | $25.00 | $13.46 | TheFly | Korro Bio initiated with a Buy at Chardan |
Latest News for KRRO
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have issued a buy rating and one
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) will take place at the following scientific conferences:
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KRRO.
U.S. House Trading
No House trades found for KRRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.